Biography builds applied intelligence for life sciences commercialization. Through AutoBio—our first proprietary AI platform—we unify science, strategy, and storytelling into a single operating layer. From early development to launch, we deliver expert-validated deep bio commercialization—faster, sharper, and leaner than legacy models.
AI Workflows Deployed
Launches Supported
Expert Strategists with PhD or MD
Guiding principles for how we think, decide, and create—anchored in science, driven by belief, delivered through expert-deployed AI.
Science
Strategy
Storytelling
Artificial Intelligence
Expert Intelligence. Platform Speed.
Vision
Realize the full promise of the Biology Century— ensuring that no potential for human advancement is left unexplored.
Mission
Accelerate how breakthrough science reaches humanity—deploying expert-validated AI platforms that transform months of strategic work into days.
Purpose
We exist to automate strategic communications for a new era of scale and complexity in life sciences—where platform velocity meets pharmaceutical rigor, and old models can't keep up.
Biography was founded with a simple conviction: that the breakthroughs of the Biology Century deserve to reach humanity, faster.
Science today is advancing at unprecedented speed—rewriting what we know about disease, health, longevity, and possibility. But innovation alone is not enough. The bottleneck isn't discovery—it's the time it takes to communicate that discovery with clarity, speed, and strategic precision.
Traditional models for strategic communications can't keep pace. What takes agencies weeks or months should take days. What requires armies of consultants should be orchestrated by intelligent systems validated by experts.
Biography was built to solve this. We deploy AI platforms that deliver expert-validated strategic communications—from competitive positioning to publication planning to launch execution. AutoBio is our first platform. More will follow. The breakthroughs of the Biology Century demand platform velocity with pharmaceutical rigor.
This is the Biology Century.
Together, we’ll deliver on its promise.
A team built to deploy AI platforms for the Biology Century—bringing together life sciences AI engineers, pharmaceutical strategists, and scientific experts with MDs and PhDs who've commercialized 50+ breakthrough therapies.
Team
Partners
Biography has built strategic partnerships with specialized firms across strategy, medical affairs, and data analytics. These partnerships extend AutoBio's capabilities—enabling platform deployment across broader use cases while maintaining our standards for regulatory compliance, scientific rigor, and strategic impact. Each partnership is chosen to complement our platform-first approach with domain-specific expertise.
01
PharmaSage
Data and Analytics
02
Fuse Health
Medical Communications
04
Caledonia Life Sciences
Strategy Consulting
Briefs
The Rise of RNA Beyond Vaccines
mRNA is finding a second act in oncology and rare disease
Context: After pandemic-era hype, RNA platforms are regaining credibility through smaller, targeted indications. Moderna, BioNTech, and new entrants are advancing personalized cancer vaccines and protein-replacement therapeutics.
Interpretation: RNA’s advantage is speed — from sequence to candidate — but long-term differentiation will depend on delivery innovation and durability of expression.
Perspective: The next wave of RNA success will come from fit-for-purpose design, not scale. Expect renewed M&A activity as delivery IP consolidates.
The AI Regulatory Submission is Coming
Draft guidance sets a framework for trustworthy AI in drug review
Context: In January 2025, the FDA issued draft guidance detailing how AI models can support regulatory decision-making across the drug and biologics lifecycle.
Interpretation: The document introduces a seven-step, risk-based framework requiring sponsors to define context of use, assess model risk, and document credibility evidence.
Perspective: FDA oversight of AI is shifting from exploration to expectation—regulatory readiness now includes transparent, validated, and well-governed AI systems.
The New Obesity-Care Economy
As GLP-1 demand surges, policy and payers are catching up.
Context: Prescriptions keep outpacing supply, and policy is shifting: OPM now requires FEHB carriers to cover at least one GLP-1 for obesity across plan options, signaling broader reimbursement momentum.
Interpretation: SELECT showed ~20% MACE reduction with semaglutide in adults with overweight/obesity without diabetes, reframing treatment as cardiovascular risk reduction, not just weight loss.
Perspective: Expect 2026 to cement obesity care as chronic CV prevention: formularies will lean on outcomes evidence and real-world data to prioritize sustained access and adherence.
Renal Denervation Enters U.S. Hypertension Care
FDA approvals create an interventional option for resistant hypertension.
Context: The FDA has cleared two renal denervation systems—Recor’s ultrasound Paradise (PMA P220023) and Medtronic’s radiofrequency Symplicity Spyral—bringing RDN into U.S. practice.
Interpretation: With approved devices, specialists gain a catheter-based adjunct for patients uncontrolled on meds; commercialization and center onboarding are underway.
Perspective: Expect 2026 focus on patient selection, payer coverage, and outcomes registries as health systems operationalize RDN at scale.
CKD Therapy Broadens Beyond Diabetes
SGLT2s cut kidney risk in CKD with or without diabetes.
Context: DAPA-CKD and EMPA-KIDNEY showed SGLT2 inhibitors reduce CKD progression and CV death across patients with and without diabetes.
Interpretation: 2025 NEJM data indicate finerenone + empagliflozin lowers albuminuria more than either alone, supporting combination strategies.
Perspective: Expect 2026 guidelines to embed earlier, combo-based kidney protection—tightening nephrology–primary care coordination.
EU JCA Reshapes Launches
Oncology and ATMPs now face an EU-wide evidence review.
Context: The EU HTA Regulation became applicable January 12, 2025, introducing joint clinical assessments (JCA) for new oncology medicines and ATMPs—centralizing comparative evidence review across Member States.
Interpretation: With JCA starting post-validation of the EMA submission, sponsors must align endpoints, comparators, and evidence packages earlier to satisfy both regulators and HTA bodies in parallel.
Perspective: Expect 2026 launches to hinge on pan-EU consistency—programs that pre-wire JCA needs with EMA dossiers will move faster to access; fragmented evidence will face delays.